Overview

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-05

Target enrollment:

Participant gender:

Summary

The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.

Phase:

PHASE1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel